Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel

References

• WHO. Eliminating measles and rubella. Framework for the verification process in the WHO European Region. 2012
   Google Scholar
• Perry RT, Gacic-Dobo M, Dabbagh A, Mulders MN, Strebel PM, Okwo-Bele JM, Rota PA, Goodson JL; Centers for Disease Control and Prevention (CDC). Global control and regional elimination of measles, 2000–2012. MMWR Morb Mortal Wkly Rep 2014; 63:103-7; PMID:24500289
   PubMed Web of Science ®Google Scholar
• WHO. Measles initiative partners gear up to tackle challenges ahead. Glob Immun News 2011; 4:1-16.
   Google Scholar
• CDC. Progress in global measles control and mortality reduction, 2000–2007. MMWR Morb Mortal Wkly Rep 2008; 57:1303; PMID:19052529
   PubMedGoogle Scholar
• Butler D. Measles by the numbers: a race to eradication. Nature 2015; 518:148-9; PMID:25673392; http://dx.doi.org/10.1038/518148a
   PubMed Web of Science ®Google Scholar
• Levin A, Burgess C, Garrison LP, Bauch C, Babigumira J, Simons E, Dabbagh A. Global eradication of measles: an epidemiologic and economic evaluation. J Infect Dis 2011; 204:S98-S106; PMID:21666220; http://dx.doi.org/10.1093/infdis/jir096
   PubMed Web of Science ®Google Scholar
• Strebel PM, Papania MJ, Fiebelkorn AP, Halsey NA. 20 – Measles vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines (Sixth Edition). London: W.B. Saunders, 2013:352-87
   Google Scholar
• Rosen B, Samuel H, Merkur S, Organization WH. Health Systems in Transition: Israel: Health System Review. Copenhagen: WHO, 2009
   Google Scholar
• Anis E, Grotto I, Moerman L, Warshavsky B, Slater PE, Lev B, Israeli A. Measles in a highly vaccinated society: the 2007–08 outbreak in Israel. J Infect 2009; 59:252-8; PMID:19683347; http://dx.doi.org/10.1016/j.jinf.2009.07.005
   PubMedGoogle Scholar
• Stein-Zamir C, Shoob H, Abramson N, Zentner G. Who are the children at risk? Lessons learned from measles outbreaks. Epidemiol Infect 2012; 140:1578-88; PMID:22117134; http://dx.doi.org/10.1017/S095026881100238X
   PubMed Web of Science ®Google Scholar
• Stein-Zamir C, Zentner G, Abramson N, Shoob H, Aboudy Y, Shulman L, Mendelson E. Measles outbreaks affecting children in Jewish ultra-orthodox communities in Jerusalem. Epidemiol Infect 2008; 136:207-14; PMID:17433131
   PubMed Web of Science ®Google Scholar
• Vandermeulen C, Mathieu R, Geert L-R, Pierre VD, Karel H. Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 2007; 25:6672-6; PMID:17692439; http://dx.doi.org/10.1016/j.vaccine.2007.07.008
   PubMedGoogle Scholar
• Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008; 197:950-6; PMID:18419470; http://dx.doi.org/10.1086/528993
   PubMed Web of Science ®Google Scholar
• Kopel E, Amitai Z, Savion M, Aboudy Y, Mendelson E, Sheffer R. Ongoing African measles virus genotype outbreak in Tel Aviv district since April, Israel, 2012. Euro Surveill 2012; 17:pii: 20272; PMID:22995430
   PubMedGoogle Scholar
• Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42; PMID:2230231; http://dx.doi.org/10.1093/infdis/162.5.1036
   PubMed Web of Science ®Google Scholar
• Crawford GE, Gremillion DH. Epidemic measles and rubella in Air Force recruits: impact of immunization. J Infect Dis 1981; 144:403-10; PMID:7310174; http://dx.doi.org/10.1093/infdis/144.5.403
   PubMedGoogle Scholar
• Levine H, Rishpon S, Huerta-Hartal M, Davidovitch N. Preventing mumps outbreaks in confined settings. Hum Vaccines 2011; 7:1389-93; PMID:22108037; http://dx.doi.org/10.4161/hv.7.12.18111
   PubMed Web of Science ®Google Scholar
• Gdalevich M, Ephros M, Mimouni D, Grotto I, Shpilberg O, Eldad A, Ashkenazi I. Measles epidemic in Israel—successful containment in the military. Prev Med 2000; 31:649-51; PMID:11133330; http://dx.doi.org/10.1006/pmed.2000.0757
   PubMedGoogle Scholar
• Andrews N, Tischer A, Siedler A, Pebody RG, Barbara C, Cotter S, Duks A, Gacheva N, Bohumir K, Johansen K, et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bull World Health Organ 2008; 86:197-204; PMID:18368206; http://dx.doi.org/10.2471/BLT.07.041129
   PubMed Web of Science ®Google Scholar
• Mimouni D, Levine H, Ferber AT, Rajuan-Galor I, Huerta-Hartal M. Secular trends of chickenpox among military population in Israel in relation to introduction of varicella zoster vaccine 1979–2010. Hum Vaccin Immunother 2013; 9:1303; PMID:23412473; http://dx.doi.org/10.4161/hv.23943
   PubMed Web of Science ®Google Scholar
• Levine H, Ankol OE, Rozhavski V, Davidovitch N, Aboudy Y, Zarka S, Balicer RD. Sub-optimal prevalence of mumps antibodies in a population based study of young adults in Israel after 20 years of two dose universal vaccination policy. Vaccine 2011; 29:2785-90; PMID:21320550; http://dx.doi.org/10.1016/j.vaccine.2011.01.103
   PubMedGoogle Scholar
• Levine H, Ankol OE, Rozhavski V, Davidovitch N, Aboudy Y, Zarka S, Balicer RD. Rubella seroprevalence in the first birth cohort reaching fertility age after 20 years of two dose universal vaccination policy in Israel. Vaccine 2012; 30:7260-4; PMID:23063839; http://dx.doi.org/10.1016/j.vaccine.2012.09.075
   PubMed Web of Science ®Google Scholar
• Eick AA, Hu Z, Wang Z, Nevin RL. Incidence of mumps and immunity to measles, mumps and rubella among US military recruits, 2000–2004. Vaccine 2008; 26:494-501; PMID:18155326; http://dx.doi.org/10.1016/j.vaccine.2007.11.035
   PubMedGoogle Scholar
• Danon Y, Adir Y, Abend I, Zaaide Y, Green M. Prevalence of antibodies against measles, mumps and rubella in Israeli young adults. Israel J Med Sci 1992; 28:733; PMID:1399506
   PubMedGoogle Scholar
• Pebody R, Gay N, Hesketh L, Vyse A, Morgan-Capner P, Brown D, Litton P, Miller E. Immunogenicity of second dose measles–mumps–rubella (MMR) vaccine and implications for serosurveillance. Vaccine 2002; 20:1134-40; PMID:11803074; http://dx.doi.org/10.1016/S0264-410X(01)00435-2
   PubMedGoogle Scholar
• Muhsen K, Abed El-Hai R, Amit-Aharon A, Nehama H, Gondia M, Davidovitch N, Goren S, Cohen D. Risk factors of underutilization of childhood immunizations in ultraorthodox Jewish communities in Israel despite high access to health care services. Vaccine 2012; 30:2109-15; PMID:22285273; http://dx.doi.org/10.1016/j.vaccine.2012.01.044
   PubMed Web of Science ®Google Scholar
• Lermarn Y, Riskin-Mashiach S, Cohen D, Slepon R, Shohat T, Harari H, Wiener M, Danon YL. Immunity to measles in young adults in Israel. Infection 1993; 21:154-7; PMID:8365813; http://dx.doi.org/10.1007/BF01710534
   PubMedGoogle Scholar
• Gdalevich M, Robin G, Mimouni D, Grotto I, Shpilberg O, Ashkenazi I. Measles antibody prevalence rates among young adults in Israel. Am J Infect Control 2002; 30:165-9; PMID:11988711; http://dx.doi.org/10.1067/mic.2002.118617
   PubMedGoogle Scholar